AU744846B2 - Therapeutic method for management of diabetes mellitus - Google Patents

Therapeutic method for management of diabetes mellitus Download PDF

Info

Publication number
AU744846B2
AU744846B2 AU68899/98A AU6889998A AU744846B2 AU 744846 B2 AU744846 B2 AU 744846B2 AU 68899/98 A AU68899/98 A AU 68899/98A AU 6889998 A AU6889998 A AU 6889998A AU 744846 B2 AU744846 B2 AU 744846B2
Authority
AU
Australia
Prior art keywords
insulin
mammal
tetracycline
agent
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU68899/98A
Other languages
English (en)
Other versions
AU6889998A (en
Inventor
Lorne M. Golub
Thomas F. Mcnamara
Nungavaram S. Ramamurthy
Maria Emanuel Ryan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Publication of AU6889998A publication Critical patent/AU6889998A/en
Application granted granted Critical
Publication of AU744846B2 publication Critical patent/AU744846B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU68899/98A 1997-06-23 1998-04-08 Therapeutic method for management of diabetes mellitus Ceased AU744846B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/880945 1997-06-23
US08/880,945 US5929055A (en) 1997-06-23 1997-06-23 Therapeutic method for management of diabetes mellitus
PCT/US1998/006927 WO1998058658A1 (en) 1997-06-23 1998-04-08 Therapeutic method for management of diabetes mellitus

Publications (2)

Publication Number Publication Date
AU6889998A AU6889998A (en) 1999-01-04
AU744846B2 true AU744846B2 (en) 2002-03-07

Family

ID=25377455

Family Applications (1)

Application Number Title Priority Date Filing Date
AU68899/98A Ceased AU744846B2 (en) 1997-06-23 1998-04-08 Therapeutic method for management of diabetes mellitus

Country Status (9)

Country Link
US (1) US5929055A (https=)
EP (1) EP1017414A4 (https=)
JP (1) JP2002511864A (https=)
KR (1) KR20010020497A (https=)
AU (1) AU744846B2 (https=)
CA (1) CA2294169A1 (https=)
IL (1) IL133643A0 (https=)
MX (1) MXPA99011821A (https=)
WO (1) WO1998058658A1 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9902721A2 (hu) 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
CA2343038A1 (en) * 1998-09-28 2000-04-06 Maria Emanuel Ryan A novel inhibitor of cataract formation
US6914057B1 (en) 1998-09-28 2005-07-05 The Research Foundation Of State University Of New York Inhibitor of cataract formation
AU2002254940A1 (en) * 2001-03-12 2002-09-24 Novartis Pharma Gmbh Combination of nateglinide or repaglinide with at least one further antidiabetic compound
EP2311440A1 (en) * 2001-04-05 2011-04-20 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
FR2826278B1 (fr) * 2001-06-20 2005-03-25 Lipha Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant
DE60216453T2 (de) * 2001-06-20 2007-09-20 Merck Santé Verwendung von antidiabetika zur herstellung eines vernarbungsfördernden arzneimittels
EP2327409A1 (en) 2001-07-13 2011-06-01 Paratek Pharmaceuticals, Inc. Tetracycline compound having target therapeutic activities
AU2002359730A1 (en) * 2001-12-21 2003-07-30 Smithkline Beecham Corporation Compositions and methods for altering glucose production
ES2551708T3 (es) 2002-01-08 2015-11-23 Paratek Pharmaceuticals, Inc. Compuestos de 4-desdimetilamino tetraciclina
EP2311451A1 (en) 2002-03-08 2011-04-20 Paratek Pharmaceuticals, Inc. Amino-methyl substituted tetracycline compounds
EP1503981A4 (en) 2002-03-21 2007-08-15 Paratek Pharm Innc SUBSTITUTED TETRACYCLINE COMPOUNDS
AU2003261161B2 (en) 2002-07-12 2009-09-10 Paratek Pharmaceuticals, Inc 3, 10, and 12a substituted tetracycline compounds
WO2004091483A2 (en) 2003-04-07 2004-10-28 Shire Laboratories, Inc. Once daily formulations of tetracyclines
AU2004259661B2 (en) 2003-07-09 2011-11-10 Paratek Pharmaceuticals, Inc. Prodrugs of 9-aminomethyl tetracycline compounds
US20050143352A1 (en) 2003-07-09 2005-06-30 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
JP5010284B2 (ja) * 2004-01-15 2012-08-29 パラテック ファーマシューティカルズ インコーポレイテッド テトラサイクリン化合物の芳香族ａ環誘導体
EP1805134B1 (en) 2004-10-25 2012-06-20 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines and methods of use thereof
EP2033950A1 (en) 2004-10-25 2009-03-11 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
US20070093455A1 (en) * 2005-07-21 2007-04-26 Paul Abato 10-substituted tetracyclines and methods of use thereof
US20070098763A1 (en) * 2005-10-11 2007-05-03 Sinnott Robert A Soluble Fiber Combinations for Weight Control and Improving Parameters of Cardiovascular Health
CA2892739A1 (en) 2006-12-21 2008-07-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of inflammatory skin disorders
WO2008079339A2 (en) 2006-12-21 2008-07-03 Paratek Pharmaceuticals, Inc. Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
EP2216323A3 (en) * 2007-04-27 2010-12-29 Paratek Pharmaceuticals, Inc. Methods for synthesizing and purifying aminoalkyl tetracycline compounds
EP2176216B1 (en) * 2007-07-06 2012-04-25 Paratek Pharmaceuticals, Inc. Methods for synthesizing 9-substituted minocycline
TWI680117B (zh) 2008-05-19 2019-12-21 派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
KR101746795B1 (ko) 2008-08-08 2017-06-13 테트라페이즈 파마슈티컬스, 인코포레이티드 Ｃ７-플루오로 치환된 테트라시클린 화합물
WO2010129057A2 (en) 2009-05-08 2010-11-11 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
NO2470500T3 (https=) 2009-08-28 2018-03-03
DK2552890T3 (en) 2010-03-31 2017-04-03 Tetraphase Pharmaceuticals Inc POLYCYCLIC TETRACYCLINE COMPOUNDS
CA2883238C (en) 2012-08-31 2021-11-23 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
EP3933845A3 (en) 2014-10-27 2022-06-22 Aseko, Inc. Subcutaneous outpatient management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
EP3337402B1 (en) 2015-08-20 2026-01-07 Glytec, LLC Diabetes management therapy advisor
HUE066360T2 (hu) 2016-10-19 2024-07-28 Tetraphase Pharmaceuticals Inc Eravaciklin kristályformái
US12570604B2 (en) 2018-11-09 2026-03-10 Tetraphase Pharmaceuticals, Inc. Polymorphic forms of a tetracycline compound and uses thereof
PH12021552866A1 (en) 2019-05-14 2022-11-07 Tyme Inc Compositions and methods for treating cancer
WO2021207487A1 (en) * 2020-04-08 2021-10-14 Hoffman Technologies Llc Methods of treating conditions characterized by insulin deficiency in animals
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013805A1 (en) * 1993-11-17 1995-05-26 Duke University Medical Center Use of nitric oxide synthase inhibitors in the treatment of autoimmune diseases
US5532227A (en) * 1992-11-17 1996-07-02 The Research Foundation Of State University Of New York Tetracyclines including non-antimicrobial chemically-modified tetracyclines inhibit excessive glycosylation of different types of collagen and other proteins during diabetes
WO1996031242A1 (en) * 1995-04-07 1996-10-10 Albert Einstein College Of Medicine Of Yeshiva University RECOMBINANT β-CELL AND USES THEREOF

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4292585A (en) * 1984-04-30 1985-11-28 Trustees Of Columbia University In The City Of New York, The Topical treatment of diabetes with insulin and penetrant enhancer applied to the skin and covered by a patch
US5045538A (en) * 1990-06-28 1991-09-03 The Research Foundation Of State University Of New York Inhibition of wasting and protein degradation of mammalian muscle by tetracyclines
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532227A (en) * 1992-11-17 1996-07-02 The Research Foundation Of State University Of New York Tetracyclines including non-antimicrobial chemically-modified tetracyclines inhibit excessive glycosylation of different types of collagen and other proteins during diabetes
WO1995013805A1 (en) * 1993-11-17 1995-05-26 Duke University Medical Center Use of nitric oxide synthase inhibitors in the treatment of autoimmune diseases
WO1996031242A1 (en) * 1995-04-07 1996-10-10 Albert Einstein College Of Medicine Of Yeshiva University RECOMBINANT β-CELL AND USES THEREOF

Also Published As

Publication number Publication date
EP1017414A4 (en) 2004-10-06
JP2002511864A (ja) 2002-04-16
AU6889998A (en) 1999-01-04
CA2294169A1 (en) 1998-12-30
IL133643A0 (en) 2001-04-30
KR20010020497A (ko) 2001-03-15
EP1017414A1 (en) 2000-07-12
WO1998058658A1 (en) 1998-12-30
MXPA99011821A (es) 2002-07-02
US5929055A (en) 1999-07-27

Similar Documents

Publication Publication Date Title
AU744846B2 (en) Therapeutic method for management of diabetes mellitus
US5859037A (en) Sulfonylurea-glitazone combinations for diabetes
US6498193B2 (en) Treatment for complications of type 2 diabetes
KR100769786B1 (ko) 메트포르민 및 글리벤클아미드의 복합을 포함하는 제약조성물
US6015803A (en) Antibiotic treatment of age-related macular degeneration
EP1128834B1 (en) Combinations for diabetes which contain glyburide,troglitazone (and a biguanide)
EP1097710B1 (en) Combination product for treating niddm
CA2389928A1 (en) Method for treating diabetes
JP2003519621A5 (https=)
Hanefeld et al. Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study
US20240100127A1 (en) Tirzepatide therapeutic methods
Kadhe et al. Advances in drug delivery of oral hypoglycemic agents
US20040176457A1 (en) Novel NIDDM regimen
US20130184350A1 (en) Novel NIDDM Regimen
Wilmshurst, EG & Twigg Which insulin? Which oral hypoglycaemic?
Riddle Combined Therapy with Insulin Plus a Sulfonylurea: The Next Step after Failure of a Sulfonylurea?
ZA200305225B (en) Spaced drug delivery system.
Diet et al. Incidence and Prevalence Data Base Treatment Report

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)